Albert M. Maguire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert M. Maguire has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Daniel C. Chung
Spark Therapeutics Inc., Philadelphia, Pennsylvania
3 shared publicationsJean Bennett
Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania; The Center for Advanced Retinal & Ocular Therapeutics, Philadelphia, Pennsylvania
3 shared publications- Jean Bennett
Perelman School of Medicine, University of Pennsylvania
3 shared publications Zi-Fan Yu
Department of Ophthalmology and Center for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium; Children’s Hospital of Philadelphia, Philadelphia, PA
3 shared publications- Amy Tillman
Department of Ophthalmology and Center for Medical Genetics Ghent, Ghent University and Ghent University Hospital, Ghent, Belgium; Children’s Hospital of Philadelphia, Philadelphia, PA
2 shared publications Bart P. Leroy
Division of Ophthalmology and Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Ophthalmology and Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium
2 shared publications
Latest Publications
- 1 March 2024
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 18 (2) , 164-167
EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS
Purpose: To determine whether maribavir is effective at treating ganciclovir-resistant cytomegalovirus retinitis. Methods: Retrospective case report of a lung-transplant patient with bilateral cytomegalovirus retinitis documented with serum and aqueous humor studies and color fundus photographs. Results: A 72-year-old lung-transplant patient with active ganciclovir-resistant cytomegalovirus was treated with intravitreal foscarnet therapy in one eye. Retinitis developed in the contralateral eye and was managed with systemic maribavir alone. Active retinitis regressed in both the eye treated with intravitreal foscarnet and the uninjected eye. Conclusion: This patient's results suggest that systemic maribavir is an effective treatment for treatment-resistant cytomegalovirus retinitis.
- 1 March 2024
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 18 (2) , 164-167
EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS
Purpose: To determine whether maribavir is effective at treating ganciclovir-resistant cytomegalovirus retinitis. Methods: Retrospective case report of a lung-transplant patient with bilateral cytomegalovirus retinitis documented with serum and aqueous humor studies and color fundus photographs. Results: A 72-year-old lung-transplant patient with active ganciclovir-resistant cytomegalovirus was treated with intravitreal foscarnet therapy in one eye. Retinitis developed in the contralateral eye and was managed with systemic maribavir alone. Active retinitis regressed in both the eye treated with intravitreal foscarnet and the uninjected eye. Conclusion: This patient's results suggest that systemic maribavir is an effective treatment for treatment-resistant cytomegalovirus retinitis.
- Open Access
- 4 June 2023
- Published by Elsevier in Current Research in Neurobiology
- Vol. 4, 100089
Dynamic structural remodeling of the human visual system prompted by bilateral retinal gene therapy
- 4 June 2023
- Published by Elsevier in Current Research in Neurobiology
- Vol. 4, 100089
Open AccessDynamic structural remodeling of the human visual system prompted by bilateral retinal gene therapy
- 14 June 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (10) , 1177-1191
Adeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
- 14 June 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (10) , 1177-1191
Adeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
- 1 February 2022
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 26 (1) , 31-34
Proliferative retinopathy and retinal detachment in pediatric atypical hemolytic uremic syndrome
- 1 February 2022
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 26 (1) , 31-34
Proliferative retinopathy and retinal detachment in pediatric atypical hemolytic uremic syndrome
- Open Access
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A37.3-A38
89 Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease
Goal To determine whether ambulatory navigation, light sensitivity, and visual field (VF) improvements 1 year after voretigene neparvovec (VN) administration in patients with biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD) are maintained at 5 years and review safety outcomes over the entire period. Methods This is an open label, randomized, controlled Phase III trial performed at 2 sites in the United States. Patients were randomized to either original intervention (OI: bilateral subretinal VN at baseline; n=20) or delayed intervention (DI: VN after 1 year; n=9). The primary endpoint was bilateral performance on the Multi-Luminance Mobility Test (MLMT) at 7 standard light levels as measured by a change in score. Additional endpoints were full-field light sensitivity threshold (FST) testing, visual acuity (VA), and Goldmann kinetic VF (GVF), each averaged over both eyes. Safety outcomes included adverse event reporting, laboratory testing, and changes in physical and ophthalmic examinations. Results For OI patients at Year 5 (n=18) and DI patients at Year 4 (n=8), the mean (standard deviation) MLMT bilateral light level score change was 1.6 (1.1) and 2.4 (1.5) levels, respectively, compared with baseline. Subsequent to the 1-year outcomes, a change of 1 light level occurred in 6 patients (none were below pre-treatment performance) and no change in the remaining 20 (N=26). Mean change in white light FST in log10 (cd.s/m2) averaged over both eyes was −2.02 (1.45) log10 at Year 5 for OI patients (n=17) and −2.58 (1.04) log10 at Year 4 for DI patients (n=8). Mean change in VA (Holladay Scale) averaged over both eyes (logMAR was −0.00 (0.64) at Year 5 for OI patients (n=18) and −0.06 (0.26) at Year 4 for DI patients (n=8). Mean change in GVF III4e sum total degrees averaged over both eyes was 166.6 (208.7) at Year 5 for OI patients (n=15) and 178.8 (241.9) at Year 4 for DI patients (n=8). Five years after treatment, the safety profile (N=29) was consistent with vitrectomy and subretinal injection procedure with 2 reports of cataract, 1 of ptosis, and 1 new report of retinal detachment since the last update. No deleterious immune responses were reported. Conclusion Improvements in ambulatory navigation, light sensitivity, and VF are maintained for at least 5 years after VN administration in most OI patients. Improvements in DI patients were consistent with those observed in OI patients. The safety profile of VN is consistent with the administration procedure.
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A37.3-A38
Open Access89 Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease
Goal To determine whether ambulatory navigation, light sensitivity, and visual field (VF) improvements 1 year after voretigene neparvovec (VN) administration in patients with biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD) are maintained at 5 years and review safety outcomes over the entire period. Methods This is an open label, randomized, controlled Phase III trial performed at 2 sites in the United States. Patients were randomized to either original intervention (OI: bilateral subretinal VN at baseline; n=20) or delayed intervention (DI: VN after 1 year; n=9). The primary endpoint was bilateral performance on the Multi-Luminance Mobility Test (MLMT) at 7 standard light levels as measured by a change in score. Additional endpoints were full-field light sensitivity threshold (FST) testing, visual acuity (VA), and Goldmann kinetic VF (GVF), each averaged over both eyes. Safety outcomes included adverse event reporting, laboratory testing, and changes in physical and ophthalmic examinations. Results For OI patients at Year 5 (n=18) and DI patients at Year 4 (n=8), the mean (standard deviation) MLMT bilateral light level score change was 1.6 (1.1) and 2.4 (1.5) levels, respectively, compared with baseline. Subsequent to the 1-year outcomes, a change of 1 light level occurred in 6 patients (none were below pre-treatment performance) and no change in the remaining 20 (N=26). Mean change in white light FST in log10 (cd.s/m2) averaged over both eyes was −2.02 (1.45) log10 at Year 5 for OI patients (n=17) and −2.58 (1.04) log10 at Year 4 for DI patients (n=8). Mean change in VA (Holladay Scale) averaged over both eyes (logMAR was −0.00 (0.64) at Year 5 for OI patients (n=18) and −0.06 (0.26) at Year 4 for DI patients (n=8). Mean change in GVF III4e sum total degrees averaged over both eyes was 166.6 (208.7) at Year 5 for OI patients (n=15) and 178.8 (241.9) at Year 4 for DI patients (n=8). Five years after treatment, the safety profile (N=29) was consistent with vitrectomy and subretinal injection procedure with 2 reports of cataract, 1 of ptosis, and 1 new report of retinal detachment since the last update. No deleterious immune responses were reported. Conclusion Improvements in ambulatory navigation, light sensitivity, and VF are maintained for at least 5 years after VN administration in most OI patients. Improvements in DI patients were consistent with those observed in OI patients. The safety profile of VN is consistent with the administration procedure.
- Top Cited PapersOpen Access
- 1 October 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (10) , 1460-1468
Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
- 1 October 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (10) , 1460-1468
Top Cited PapersOpen AccessDurability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
- Open Access
- 1 October 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (10) , 661-663
Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65 -Associated Leber's Congenital Amaurosis
Leber's congenital amaurosis (LCA) is a rare inherited retinal degeneration (IRD) that causes severe vision loss, nyctalopia, and nystagmus within the first few years of life. RPE65 gene mutations cause approximately 6% of LCA cases and have become the target for therapy since voretigene neparvovec-rzyl became the first U.S. Food and Drug Administration-approved gene therapy product for IRDs in 2017. The surgery involves pars plana vitrectomy with subretinal injection of a viral vector that carries a functional copy of the RPE65 gene. Intraoperative optical coherence tomography is a useful adjunctive tool to confirm the injection has reached the subretinal space.
- 1 October 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (10) , 661-663
Open AccessSubretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65 -Associated Leber's Congenital Amaurosis
Leber's congenital amaurosis (LCA) is a rare inherited retinal degeneration (IRD) that causes severe vision loss, nyctalopia, and nystagmus within the first few years of life. RPE65 gene mutations cause approximately 6% of LCA cases and have become the target for therapy since voretigene neparvovec-rzyl became the first U.S. Food and Drug Administration-approved gene therapy product for IRDs in 2017. The surgery involves pars plana vitrectomy with subretinal injection of a viral vector that carries a functional copy of the RPE65 gene. Intraoperative optical coherence tomography is a useful adjunctive tool to confirm the injection has reached the subretinal space.
- Top Cited PapersOpen Access
- 1 September 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (9) , 1273-1285
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy
- 1 September 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (9) , 1273-1285
Top Cited PapersOpen AccessEfficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy
- 1 March 1997
- Published by Elsevier in Experimental Eye Research
- Vol. 64 (3) , 487-490
Letter to the Editor: A Carboxy-terminal Truncation of 99 Amino Acids Resulting from a Novel Mutation (Arg555→stop) in theCHMGene leads to Choroideremia
- 1 March 1997
- Published by Elsevier in Experimental Eye Research
- Vol. 64 (3) , 487-490
Letter to the Editor: A Carboxy-terminal Truncation of 99 Amino Acids Resulting from a Novel Mutation (Arg555→stop) in theCHMGene leads to Choroideremia
- Open Access
- 1 January 1995
- Published by Elsevier in Survey of Ophthalmology
- Vol. 39 (4) , 302-306
von Hippel-Lindau disease manifesting as a chiasmal syndrome
- 1 January 1995
- Published by Elsevier in Survey of Ophthalmology
- Vol. 39 (4) , 302-306
Open Accessvon Hippel-Lindau disease manifesting as a chiasmal syndrome